Drugs / LY4066708
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07046559 | May 2025 → Sep 2027 expected | cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4066708 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07046559 ↗ |
| Route | Intravenous | “LY4066708 administered by intravenous (IV) injection” NCT07046559 ↗ |